Anupama Nehra, MD
Hematology & Oncology · Newark, NJNPI 1811935307
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,405 of the $9,055 with a category attached, or 70.7%. Merck accounts for 98.8% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2023 at $8,840 and has fallen 98.8% since, to $103 in 2024.
Across 20 payments — averaging $452.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$9K
- Johnson & Johnson$100
- Gilead$12
Across 24 payments — averaging $38,155 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$916K
What the payments were for
- Consulting fees$6,40571%
- Travel & lodging$1,84020%
- Food & beverage$6988%
- Education$1121%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 18 | $8,943 |
| Johnson & Johnson | 1 | $100 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KEYTRUDA$8,551
How this compares
$9,055 in reported general payments places this provider in the 70th percentile of 362 hematology & oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 17 | $289,227 |
| KisqaliRibociclib Succinate | 14 | $186,266 |
| Everolimus | 12 | $26,499 |
| Exemestane | 28 | $4,593 |
| Anastrozole | 87 | $1,425 |
| Prochlorperazine Maleate | 48 | $1,174 |
| Letrozole | 53 | $917 |
| Dexamethasone | 26 | $471 |
| LoperamideLoperamide Hcl | 26 | $198 |
| Gabapentin | 16 | $168 |
| Ondansetron Hcl | 22 | $161 |
| Carvedilol | 14 | $40 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Newark
- Alice CohenNewark$21K
- Robert SpiegelWestfield$864K
- Amit PatelJersey City$770K
- Joshua StraussSpringfield$739K
- Charles FarberMorristown$609K
- Michael ScolaMorristown$506K
- Eshan PatelSomerville$420K
- Arturo Loaiza-BonillaPennington$406K
- Ashish ShahSpringfield$394K
- Carl HenningsonManasquan$349K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.